Nanotechnology-driven nanoemulsion gel for enhanced transdermal delivery of Sophora alopecuroides L. empyreumatic oil: formulation optimization, and anti-biofilm efficacy

Xin Cheng, Xiangyu Zhou, Wenping Wang, Jing Chen, Yikun Cao, Jiangqi Wen, Hu JinFrontiers in Bioengineering and Biotechnology 2025 · DOI

Abstract

Sophora alopecuroides L. empyreumatic oil (SoA oil) shows therapeutic potential for psoriasis and eczema but is limited by poor skin permeability and formulation challenges. This study developed a nanoemulsion (NE) gel to overcome these hurdles. Optimized using pseudo-ternary phase diagrams, the NE featured a mean droplet size of 53.27 nm and a zeta potential of -38.13 mV. Incorporation into a 2% carbomer 940 gel enhanced viscoelasticity. In vitro tests showed superior skin permeability and higher cutaneous retention of the marker oxymatrine compared to raw oil. In vivo rabbit tests confirmed the NE gel eliminated the moderate irritation caused by raw SoA oil. Furthermore, the NE demonstrated significantly enhanced anti-biofilm activity against Staphylococcus aureus and MRSA, highlighting its potential for treating biofilm-associated dermatological infections.

Introduction

Sophora alopecuroides L. (SoA) oil is a traditional herbal remedy valued for its potent anti-inflammatory and antibacterial properties. It is a promising candidate for treating chronic skin conditions such as psoriasis and eczema. However, clinical application is hindered by several practical challenges: the oil has poor skin permeability, a dark color, a pungent odor, and a tendency to adhere to wounds, which reduces patient compliance.

Moreover, many dermatological infections are complicated by the formation of biofilms—resilient bacterial communities encased in a protective extracellular matrix. Conventional treatments often fail to penetrate these barriers. This research aimed to develop a nanotechnology-driven delivery system capable of bypassing the skin's stratum corneum while enhancing the oil's efficacy against these resilient bacterial colonies.

Methodology

The research team employed a nanoemulsion (NE) strategy to disperse the SoA oil into nanoscale droplets within an aqueous base.

Formulation and Optimization

Pseudo-ternary phase diagrams were utilized to identify the optimal ratio of surfactants (Cremophor EL) and co-surfactants (PEG 400) to ensure a stable nanoemulsion region. To transition the liquid NE into a form suitable for topical application, it was incorporated into a Carbomer 940 (CP940) gel matrix. This formulation was compared against other gelling agents, such as HPMC and CMC-Na, through rheological studies to ensure ideal viscosity and thixotropic behavior.

Characterization and Tracking

The NE was characterized for droplet size, polydispersity index (PDI), and zeta potential. To track the delivery efficiency, oxymatrine, a primary alkaloid found in SoA, was used as a chemical marker. Skin permeability and retention were assessed in vitro using Franz diffusion cells with Kunming rat skin, and oxymatrine levels were quantified via HPLC.

Chemical constituents and plant morphology of Sophora alopecuroides L., including key markers like oxymatrine and matrine.

Biological Assays

The safety profile was evaluated through in vivo skin irritation tests on rabbit dorsal skin. Anti-biofilm efficacy was tested against Staphylococcus aureus (ATCC 6538) and Methicillin-resistant S. aureus (MRSA, ATCC 43300) to measure both biofilm inhibition and the clearance of mature biofilms.

Results and Discussion

Physical Properties and Skin Penetration

The optimized nanoemulsion achieved a mean droplet size of 53.27 nm with a PDI of 0.236. This small size is critical for providing a large surface area for drug release and allowing droplets to navigate the skin's lipid bilayers effectively. The NE gel demonstrated a cutaneous retention of oxymatrine at 19.8 μg/cm², which is nearly 4.5 times higher than that of raw SoA oil (4.4 μg/cm²).

Safety and Irritation

A significant finding was the improvement in the safety profile. Raw SoA oil caused moderate skin irritation in rabbits, scoring a 4 after 72 hours. In contrast, both the NE and the NE gel formulations resulted in zero irritation (score of 0). Encapsulating the oil within nano-droplets appears to shield the skin from the harsher components of the raw extract.

Anti-Biofilm Efficacy

The NE formulations showed superior performance against bacterial biofilms:

  • Inhibition: At 12.50 mg/mL, the NE and the gel achieved inhibition rates of 81.7% and 82.1% against S. aureus, respectively, compared to 78.3% for the raw oil.
  • Clearance: Against MRSA, the NE and the gel achieved clearance rates of 42.7% and 43.9% respectively at 12.50 mg/mL, significantly outperforming the raw oil's 31.9% (P < 0.0001).
  • Low Concentration Performance: The NE was particularly effective at low concentrations (0.09766 mg/mL), showing an 8.9% inhibition rate compared to just 2.0% for the raw oil.

The surfactant components of the NE likely assist in disrupting the protective extracellular polymeric substance (EPS) matrix of the biofilm, allowing the active herbal components to reach the bacteria.

Conclusion

The development of a nanotechnology-driven nanoemulsion gel represents a significant advancement in the topical delivery of Sophora alopecuroides L. empyreumatic oil. By enhancing skin penetration and eliminating irritation, this formulation addresses the primary barriers to the clinical use of SoA oil. Its superior anti-biofilm activity, particularly against MRSA, suggests it could be a potent tool in treating complex, biofilm-associated dermatological infections. Future work should focus on long-term stability and in vivo efficacy in infected wound models.

Summary updated

Abstract

<i>Sophora alopecuroides L.</i> empyreumatic oil (SoA oil) exhibits therapeutic potential for psoriasis and eczema but suffers from poor skin permeability and formulation challenges. To overcome these limitations, a nanoemulsion (NE) gel was developed. The NE was optimized using pseudo-ternary phase diagrams and characterized for droplet size, polydispersity index (PDI), zeta potential, and rheological properties. Skin permeability and retention were assessed <i>in vitro</i> using Franz diffusion cells, with oxymatrine quantified by HPLC. <i>In vivo</i> skin irritation was tested on rabbit dorsal skin, and anti-biofilm activity was evaluated against <i>Staphylococcus aureus</i> (<i>S</i>. <i>aureus</i>) and methicillin-resistant <i>S. aureus</i> (MRSA). A final concentration of 5% SoA oil in the NE formulation was used for subsequent studies. The optimized SoA oil NE (the NE) had a mean droplet size of 53.27 nm, PDI of 0.236, and zeta potential of -38.13 mV. Adding 2% carbomer 940 (CP940) to the gel enhanced viscoelasticity. The NE showed superior skin permeability and higher cutaneous retention of oxymatrine. SoA oil caused moderate irritation to the skin of rabbits, while the other two formulations did not. The NE demonstrated enhanced biofilm inhibition against <i>S. aureus</i> at 0.09766 mg/mL, with an 8.9% rate surpassing SoA oil (2.0%) and SoA oil NE gel (the gel, 4.0%). At 12.50 mg/mL, the NE and the gel achieved slightly higher inhibition rates (81.7% and 82.1%, respectively) than SoA oil (78.3%). Notably, the NE showed significantly greater anti-biofilm effects against MRSA within the concentration range from 0.09766 to 3.12 mg/mL (<i>P</i> < 0.001). In mature biofilm clearance against <i>S. aureus</i>, the NE demonstrated a clearance rate of 4.9% at 0.09766 mg/mL, while SoA oil and the NE gel achieved clearance rates of 2.3% and 0.8%, respectively. At a higher concentration of 12.50 mg/mL, the clearance rate for the NE increased to 38.1%, significantly outperforming SoA oil (29.1%) and the NE gel (36.4%). Against MRSA, the NE and the gel displayed significantly improved clearance at 12.50 mg/mL (42.7% and 43.9%, respectively) compared to SoA oil (31.9%) (<i>P</i> < 0.0001). These findings highlight the potential of nanotechnology-driven delivery systems to improve the clinical application of herbal extracts for treating biofilm-associated dermatological infections.
BibTeX
@inproceedings{cheng2025nanotechnology,
  author = {Xin Cheng and Xiangyu Zhou and Wenping Wang and Jing Chen and Yikun Cao and Jiangqi Wen and Hu Jin},
  title = {{Nanotechnology-driven nanoemulsion gel for enhanced transdermal delivery of Sophora alopecuroides L. empyreumatic oil: formulation optimization, and anti-biofilm efficacy}},
  booktitle = {Frontiers in Bioengineering and Biotechnology},
  year = {2025},
  doi = {10.3389/fbioe.2025.1586924},
}
Figure